Emily Leproust Sells 1,687 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Posted by Stanley Muller on Sep 23rd, 2026

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) CEO Emily Leproust sold 1,687 shares of the firm’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $165.49, for a total transaction of $279,181.63. Following the transaction, the chief executive officer directly owned 618,902 shares of the company’s stock, valued at $102,422,091.98. The trade was a 0.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Trading Down 3.7%

Shares of NASDAQ:TWST traded down $6.10 during mid-day trading on Wednesday, reaching $158.50. 2,133,311 shares of the company’s stock were exchanged, compared to its average volume of 1,563,605. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $170.66. The firm has a market capitalization of $9.94 billion, a price-to-earnings ratio of -71.40 and a beta of 2.22. The business’s fifty day moving average price is $121.94 and its 200-day moving average price is $84.72.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The company had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.33 earnings per share. On average, research analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on TWST shares. BWS Financial reaffirmed a “sell” rating and issued a $45.00 price objective on shares of Twist Bioscience in a research note on Friday, September 18th. Piper Sandler increased their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. Barclays raised their price target on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Robert W. Baird boosted their price target on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Finally, Guggenheim reiterated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 24th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $103.00.

View Our Latest Analysis on Twist Bioscience

Institutional Investors Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC raised its holdings in shares of Twist Bioscience by 24.4% during the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after buying an additional 185 shares in the last quarter. Allworth Financial LP raised its holdings in Twist Bioscience by 54.9% during the 2nd quarter. Allworth Financial LP now owns 601 shares of the company’s stock valued at $62,000 after buying an additional 213 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after buying an additional 453 shares during the last quarter. Trifecta Capital Advisors LLC purchased a new stake in Twist Bioscience during the 2nd quarter valued at $63,000. Finally, Intech Investment Management LLC boosted its position in Twist Bioscience by 2.6% during the 4th quarter. Intech Investment Management LLC now owns 25,477 shares of the company’s stock valued at $808,000 after buying an additional 643 shares during the period.

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.